Patricia Martin-Romano
Overview
Explore the profile of Patricia Martin-Romano including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
319
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aldea M, Tagliamento M, Bayle A, Vasseur D, Verge V, Marinello A, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200583.
PMID: 36862966
Purpose: High-risk clonal hematopoiesis (CH) is frequently incidentally found in patients with solid tumors undergoing plasma cell-free DNA sequencing. Here, we aimed to determine if the incidental detection of high-risk...
2.
Michot J, Quivoron C, Sarkozy C, Danu A, Lazarovici J, Saleh K, et al.
Am J Hematol
. 2023 Jan;
98(4):645-657.
PMID: 36606708
Advances in molecular profiling of newly diagnosed diffuse large B-cell lymphoma (DLBCL) have recently refine genetic subgroups. Genetic subgroups remain undetermined at the time of relapse or refractory (RR) disease....
3.
Martin-Romano P, Mezquita L, Hollebecque A, Lacroix L, Rouleau E, Gazzah A, et al.
JCO Precis Oncol
. 2022 Oct;
6:e2100484.
PMID: 36315916
Purpose: To facilitate implementation of precision medicine in clinical management of cancer, the European Society of Medical Oncology proposed in 2018 a new scale to harmonize and standardize the reporting...
4.
Martin-Romano P, Colmet-Daage L, Morel D, Baldini C, Verlingue L, Bahleda R, et al.
Eur J Cancer
. 2022 Jul;
173:133-145.
PMID: 35872509
Introduction: Although the role of epigenetic alterations in oncogenesis has been well studied, their prevalence in metastatic solid tumours is still poorly described. We therefore aimed at: (i) describing the...
5.
Baldini C, Danlos F, Varga A, Texier M, Halse H, Mouraud S, et al.
J Exp Clin Cancer Res
. 2022 Jul;
41(1):217.
PMID: 35794623
Background: We aimed to determine the safety and efficacy of nintedanib, an oral anti-angiogenic tyrosine kinase inhibitor, in combination with pembrolizumab, an anti-PD1 immunotherapy, in patients with advanced solid tumors...
6.
Vasseur D, Sassi H, Bayle A, Tagliamento M, Besse B, Marzac C, et al.
Cells
. 2022 Jun;
11(12).
PMID: 35741030
FDA-approved next-generation sequencing assays based on cell-free DNA offers new opportunities in a molecular-tumor-board context thanks to the noninvasiveness of liquid biopsy, the diversity of analyzed parameters and the short...
7.
Hollebecque A, Salvagni S, Plummer R, Niccoli P, Capdevila J, Curigliano G, et al.
Cancer
. 2022 Jun;
128(17):3185-3195.
PMID: 35737639
Background: CC-90011 is an oral, potent, selective, reversible inhibitor of lysine-specific demethylase 1 (LSD1) that was well tolerated, with encouraging activity in patients who had advanced solid tumors or relapsed/refractory...
8.
Tamborero D, Dienstmann R, Rachid M, Boekel J, Lopez-Fernandez A, Jonsson M, et al.
Nat Cancer
. 2022 Apr;
3(5):649.
PMID: 35449310
No abstract available.
9.
Guiard E, Baldini C, Pobel C, Assi T, Bernard-Tessier A, Martin-Romano P, et al.
Eur J Cancer
. 2022 Apr;
167:42-53.
PMID: 35378410
Background: Immune checkpoint blockers (ICBs) in combination with antiangiogenic drugs showed synergistic efficacy in several tumour types. New patterns of progression have recently been defined upon treatment with ICB alone...
10.
Wang J, Martin-Romano P, Cassier P, Johnson M, Haura E, Lenox L, et al.
Oncologist
. 2022 Mar;
27(7):536-e553.
PMID: 35325211
Background: Patients with KRAS-mutant cancers have limited treatment options. Here we present a phase I study of JNJ-74699157, an oral, selective, covalent inhibitor of the KRAS G12C isoform, in patients...